5-Cyano-prostacyclin derivatives and use as medicines
    3.
    发明授权
    5-Cyano-prostacyclin derivatives and use as medicines 失效
    5-Cyano-prostacyclin衍生物用作药物

    公开(公告)号:US4364950A

    公开(公告)日:1982-12-21

    申请号:US317621

    申请日:1981-11-02

    摘要: 5-cyano-prostacyclins of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ; R.sub.2 and R.sub.3 each independently is (a) H, (b) C.sub.1-10 -alkyl, (c) C.sub.1-10 -alkyl substituted by halo, C.sub.1-4 -alkoxy or phenyl, 1-naphthyl or 2-naphthyl, each optionally substituted as defined below, (d) C.sub.4-10 -cycloalkyl, (e) C.sub.4-10 -cycloalkyl substituted by C.sub.1-4 -alkyl, (f) phenyl, 1-naphthyl or 2-naphthyl, (g) phenyl, 1-naphthyl or 2-naphthyl substituted by 1-3 halogen atoms, phenyl, 1-3 alkyl groups of 1-4 C atoms each, or a chloromethyl-, fluoromethyl-, trifluoromethyl-, carboxyl-, hydroxy- or alkoxy-group of 1-4 C atoms, or (h) an aromatic, 5- or 6-membered heterocyclic ring containing one hetero atom which is O, N or S, the remaining atoms being carbon; R.sub.3 also possibly being an acyl group of a C.sub.1-15 -hydrocarbon carboxylic or sulfonic acid;B is straight chain or branched alkylene of 2-10 C atoms;W is hydroxymethylene or ##STR2## wherein the OH group may be in the alpha or beta position, and is optionally modified by replacement of the H atom of the OH with an ether or acyl group which is conventional for such replacements in prostaglandins and which is readily cleavable at physiological pH's;R.sub.4 is hydroxy, optionally modified as described for W above;R.sub.5, R.sub.6, R.sub.7 and R.sub.8 each independently is hydrogen, alkyl of 1-5 C atoms or methoxy; andR.sub.9 is alkyl of 1-5 C atoms orfor compounds wherein R.sub.2 is H, the salts thereof with physiologically compatible bases have valuable pharmacalogical properties, e.g., hypertonic and bronchodilatory activities.

    摘要翻译: 其中R1是OR2或NHR3的式“IMAGE”的5-氰基 - 前列环素; R 2和R 3各自独立地为(a)H,(b)C 1-10 - 烷基,(c)被卤素,C 1-4 - 烷氧基或苯基,1-萘基或2-萘基取代的C 1-10 - 烷基, (d)C 4-10 - 环烷基,(e)被C 1-4 - 烷基取代的C 4-10 - 环烷基,(f)苯基,1-萘基或2-萘基,(g)苯基, 萘基或被1-3个卤素原子取代的2-萘基,苯基,1-4个C原子的1-3个烷基,或1个氯甲基 - ,氟甲基 - ,三氟甲基 - ,羧基 - ,羟基或烷氧基 -4个C原子,或(h)含有一个杂原子的芳族的5或6元杂环,它是O,N或S,其余的原子是碳; R3也可能是C1-15-烃羧酸或磺酸的酰基; B是2-10个C原子的直链或支链亚烷基; W是羟基亚甲基或其中OH基团可以在α或β位置,并且任选地通过用在前列腺素中这种替代物常规的醚或酰基取代OH的H原子来任意修饰,并且其是 在生理pH值下易于切割; R4是羟基,任选地按照上述W所述进行改性; R5,R6,R7和R8各自独立地为氢,1-5个C原子的烷基或甲氧基; 并且R 9为1-5个C原子的烷基,或对于其中R 2为H的化合物,其与生理上相容的碱的盐具有有价值的药理学性质,例如高渗和支气管扩张活性。

    Prostaglandin-I.sub.2 derivatives
    5.
    发明授权
    Prostaglandin-I.sub.2 derivatives 失效
    前列腺素I2衍生物

    公开(公告)号:US4191694A

    公开(公告)日:1980-03-04

    申请号:US928126

    申请日:1978-07-26

    摘要: Prostane derivatives of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ;R.sub.2 is hydrogen, C.sub.1-10 alkyl, C.sub.4-10 cycloalkyl, C.sub.6-10 aryl, or a 5 or 6 membered heterocyclic ring having 1-3 hetero atoms selected from O, N and S;R.sub.3 is the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms;W is (a) an OH-substituted methylene group, (b) a ##STR2## wherein the OH-groups in (a) or (b) can be in the .alpha.- or .beta.-position, or (c) such a group wherein the H atom of the OH group is replaced by the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms or by a conventional etherifying OH-blocking group;R.sub.4 is OH or hydroxy whose H atom is replaced as defined for W; andR.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 each independently is hydrogen or alkyl of 1-5 carbon atoms; or R.sub.9 and R.sub.10 together represent a direct bond; and, when R.sub.11 is alkyl, R.sub.10 can also be chlorine;and, for a derivative wherein R.sub.2 is hydrogen, the salts thereof with physiologically compatible bases,have improved prostaglandin activity.

    摘要翻译: 其中R1为OR2或NHR3的式(Ⅰ)所示的前驱体衍生物; R2是氢,C1-10烷基,C4-10环烷基,C6-10芳基或具有1-3个选自O,N和S的杂原子的5或6元杂环; R3是1-15个碳原子的烃羧酸或磺酸的残基; W是(a)OH-取代的亚甲基,(b)其中(a)或(b)中的OH基可以是α或β-位,或(c)这样的基团 其中OH基团的H原子被1-15个碳原子的烃羧酸或磺酸的残基或通过常规的醚化OH-封闭基团取代; R4是OH或羟基,其H原子被替换为W定义; R 5,R 6,R 7,R 8,R 9,R 10和R 11各自独立地为氢或1-5个碳原子的烷基; 或R 9和R 10一起代表直接键; 当R 11为烷基时,R 10也可为氯; 并且对于其中R 2是氢的衍生物,其与生理上相容的碱的盐具有改善的前列腺素活性。

    Azaprostacyclins, their preparation and pharmaceutical use
    6.
    发明授权
    Azaprostacyclins, their preparation and pharmaceutical use 失效
    阿沙普罗环素,其制备和药物用途

    公开(公告)号:US4567195A

    公开(公告)日:1986-01-28

    申请号:US591719

    申请日:1984-03-21

    摘要: Azaprostacyclins of Formula I ##STR1## wherein R.sub.1 is hydrogen, alkyl, cycloalkyl, aryl, a heterocyclic residue, or a phenacyl residue optionally substituted on the phenyl ring by bromine, phenyl, alkoxy, or dialkoxy,W is a free or functionally modified carbonyl group or a ##STR2## wherein R.sub.8 is hydrogen or alkyl of 1-5 carbon atoms and R.sub.9 is hydrogen or a readily cleavable ether or acyl residue and wherein the OR.sub.9 -group can be in the .alpha.- or .beta.-position,R.sub.2 is a free or functionally modified hydroxy group,R.sub.3 and R.sub.4 each independently is hydrogen, alkyl of 1-5 carbon atoms, or fluorine,D is alkylene of 1-2 carbon atoms which can be substituted by alkyl groups of 1-5 carbon atoms,R.sub.5 is hydrogen or alkyl of 1-2 carbon atoms or, when D is alkylene of 1 or 2 carbon atoms, R.sub.5, together with R.sub.6, represents a bond,R.sub.6 and R.sub.7 each independently is hydrogen or alkyl of 1-2 carbon atoms, whereinR.sub.6 (R.sub.7) is halogen when R.sub.7 (R.sub.6), respectively, is alkyl of 1-2 carbon atoms orR.sub.5 and R.sub.7 each independently is hydrogen or alkyl of 1-2 carbon atoms whenD and R.sub.6 together form a carbocyclic ring closed via (CH.sub.2).sub.1-3 with D as --CH

    摘要翻译: 式I的阿沙普罗环素其中R 1是氢,烷基,环烷基,芳基,杂环残基或任选在苯环上被溴,苯基,烷氧基或二烷氧基取代的苯甲酰甲基残基,W是游离或 官能改性的羰基或其中R8是氢或1-5个碳原子的烷基,R9是氢或易裂解的醚或酰基残基,其中OR9-基团可以是α-或β-位, R2是游离的或官能改性的羟基,R 3和R 4各自独立地是氢,1-5个碳原子的烷基或氟,D是可以被1-5个碳原子的烷基取代的1-2个碳原子的亚烷基 原子,R5是氢或1-2个碳原子的烷基,或当D是1或2个碳原子的亚烷基时,R5与R6一起代表键,R6和R7各自独立地是氢或1-2碳的烷基 原子,其中当R 7(R 6)分别为1-2个碳原子的烷基或R 5和R 7 eac时,R 6(R 7)为卤素 h独立地为氢或1-2个碳原子的烷基,当D和R6一起形成通过(CH 2)1-3封闭的碳环,其中D为-CH 3且R 6为-CH 2 - ,当R 1为氢时, 其与碱的生理上相容的盐具有有价值的药理学性质,例如降血压和支气管扩张活性。

    Carbacyclins, process for the preparation thereof, and use thereof as
medicinal agents
    8.
    发明授权
    Carbacyclins, process for the preparation thereof, and use thereof as medicinal agents 失效
    卡巴菌素,其制备方法及其作为药剂的用途

    公开(公告)号:US5124343A

    公开(公告)日:1992-06-23

    申请号:US141233

    申请日:1988-01-06

    摘要: The invention relates to carbacyclins of general Formula I ##STR1## wherein R.sub.1 is the residue CH.sub.2 OH or ##STR2## with R.sub.2 meaning a hydrogen atom, an alkyl, cycloalkyl, aryl residue, a ##STR3## or heterocyclic residue, or R.sub.1 is the residue ##STR4## with R.sub.3 meaning an alkanoyl or alkanesulfonyl residue of respectively 1-10 carbon atoms or the residue R.sub.2, orR.sub.1 is the residue ##STR5## wherein m is the number 1 or 2, X is an oxygen atom or a CH.sub.2 -group,A is a trans--CH.dbd.CH- or --.tbd.C--group,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.- position,n is the number 1, 2, or 3,D is a straight-chain alkylene group of 1-5 carbon atoms,E is a --C.tbd.C---bond or a --CR.sub.6 =CR.sub.7 --group wherein R.sub.6 and R.sub.7 are different from each other and mean a hydrogen atom or an alkyl group of 1-5 carbon atoms or a hydrogen atom or a halogen atom, preferably chlorine,R.sub.4 is an alkyl, cycloalkyl, or optionally substituted arly group, or a heterocyclic group,R.sub.5 is a free or functionally modified hydroxy group, andif R.sub.2 means a hydrogen atom, the salts thereof with physiologically compatible bases;to processes for the preparation thereof, and to the use thereof as blood-pressure-lowering agents.

    摘要翻译: 本发明涉及通式I的碳霉素,其中R 1是残基CH 2 OH或R 2,其中R 2表示氢原子,烷基,环烷基,芳基,芳基或杂环残基,或者R 1是 残基其中R3表示分别为1-10个碳原子的烷酰基或烷磺酰基残基或残基R2,或R1为残基,其中m为数1或2,X为氧原子或CH2- 基团,A是反式-CH = CH-或 - 3BOND C-基团,W是游离或官能改性的羟基亚甲基基团,其中OH-基团可以是α或β位置,n是数1,2 或3,D是1-5个碳原子的直链亚烷基,E是-C3OND C键或-CR6 = CR7-基团,其中R6和R7彼此不同,意指氢 原子或1-5个碳原子的烷基或氢原子或卤素原子,优选氯,R4是烷基,环烷基或任选取代的芳基或杂环基团 p,R5是游离或功能改性的羟基,如果R 2表示氢原子,则其与生理上相容的碱的盐; 其制备方法及其作为降血压剂的用途。

    Certain 5-cyano-16-fluoro-prostacyclins and their use as pharmaceuticals
    9.
    发明授权
    Certain 5-cyano-16-fluoro-prostacyclins and their use as pharmaceuticals 失效
    某些5-氰基-16-氟前列环素及其作为药物的用途

    公开(公告)号:US4378370A

    公开(公告)日:1983-03-29

    申请号:US309967

    申请日:1981-10-06

    摘要: Prostacyclin derivatives of the formula ##STR1## wherein R.sub.1 is OR.sub.3 wherein R.sub.3 is hydrogen or alkyl of 1-10 carbon atoms, or R.sub.1 is NHR.sub.4 wherein R.sub.4 is alkanoyl or alkanesulfonyl,B is alkylene of 1-5 carbon atoms,A is --CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH--, or trans--CH.dbd.CH--,W is hydroxymethylene or ##STR2## wherein the OH-group is optionally substituted by alkanoyl of 1-4 carbon atoms and the free or substituted OH-group can be in the .alpha.- or .beta.- position,R.sub.2 is alkyl of 1-6 carbon atoms optionally substituted by phenyl, or R.sub.2 is phenyl,R.sub.5 is hydroxy optionally substituted by alkanoyl of 1-4 carbon atoms,R.sub.6 is hydrogen, fluorine, or alkyl of 1-4 carbon atomsor when R.sub.3 is hydrogen, a salt thereof with a physiologically compatible base,have pharmacological activity e.g., blood pressure-lowering and bronchodilatory effects.

    摘要翻译: PCT No.PCT / DE81 / 00031 Sec。 371日期1981年10月6日 102(e)日期1981年10月6日PCT提交1981年2月5日PCT公布。 出版物WO81 / 02296 日本1981年8月20日。其中R 1为OR 3的式(I)其中R 3为氢或1-10个碳原子的烷基,或R 1为NHR 4,其中R 4为烷酰基或链烷磺酰基,B为1- 5个碳原子,A是-CH 2 -CH 2 - ,顺式-CH = CH-或反式-CH = CH-,W是羟基亚甲基或其中OH基任选被1-4个碳原子的烷酰基取代 并且游离或取代的OH基团可以在α或β位,R 2是任选被苯基取代的1-6个碳原子的烷基,或者R 2是苯基,R 5是任选被1-4碳的烷酰基取代的羟基 原子,R6是氢,氟或1-4个碳原子的烷基,或当R3是氢时,其与生理上相容的碱的盐具有药理活性,例如降血压和支气管扩张作用。